Maze Therapeutics, Inc.
About
26.46USD+0.06 +0.23%
Closed • Updated at 04:24 GMT+00:00Market Cap$1.46B
Volume674.5K
Beta1.04
RSI47.23
Gross Margin89.19%
Maze Therapeutics, Inc. — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 22 2026
Maze Therapeutics Announces $150 Million Registered Offering
Mar 25 2026
Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
Mar 25 2026
Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease
Feb 25 2026
Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
Feb 4 2026
Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Recent Videos
MindMaze Therapeutics – executive interview (11 May 2026)
May 11, 2026
MAZE, Maze Therapeutics, Inc. stock prices historical data
Apr 26, 2026
Episode 157 - Harold Bernstein - President R&D Maze Therapeutics
Apr 22, 2026
Precision Medicine Got Kidney Disease Wrong—Until Now
Apr 01, 2026
Community Chat
Ask AI
Try asking